Imara, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. -2.76%35.620.9%$906.75m
JNJJohnson & Johnson -3.21%144.390.7%$899.38m
MRKMerck & Co., Inc. -3.66%82.670.7%$683.04m
ABBVAbbVie, Inc. -2.51%87.851.9%$646.62m
BMYBristol-Myers Squibb Co. -3.12%57.421.0%$552.36m
LLYEli Lilly & Co. -2.23%150.741.1%$539.74m
AZNAstraZeneca Plc -2.05%55.291.2%$247.85m
NVSNovartis AG -2.23%88.910.2%$162.79m
PRNBPrincipia Biopharma, Inc. -0.31%99.960.0%$117.69m
GSKGlaxoSmithKline Plc -3.03%38.070.2%$97.47m
CVACCureVac NV -5.93%49.000.0%$68.46m
NVONovo Nordisk A/S -1.40%68.470.1%$53.48m
RGENRepligen Corp. -4.25%139.787.1%$52.13m
OPKOPKO Health, Inc. 1.21%3.2111.2%$47.83m
SNYSanofi -3.77%50.470.2%$47.20m

Company Profile

Imara, Inc. engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. Its product candidate, IMR-687 is a highly selective and small molecule inhibitor of PDE9. The company was founded by James G. McArthur in 2016 and is headquartered in Cambridge, MA.